We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 11-20 of 2,475

Expanded FTC premerger notification rules specific to the pharmaceutical industry are upheld by the D.C. Circuit
  • Kelley Drye & Warren LLP
  • USA
  • June 19 2015

The D.C. Circuit recently affirmed a lower court's decision upholding regulations adopted by the Federal Trade Commission (FTC) requiring a Hart


“Ain’t wastin’ time no more” doctors, vets, and lawyers in the antitrust crosshairs
  • Baker & Hostetler LLP
  • USA
  • June 18 2015

Earlier this month a Texas federal district court judge granted a motion by Teladoc, Inc. (Teladoc) for a preliminary injunction enjoining the Texas


Second Circuit rules that "product hopping" may constitute unlawful monopolization; pharmaceutical companies are likely targets of future antitrust enforcement
  • Cooley LLP
  • USA
  • June 12 2015

Recent antitrust challenges to pharmaceutical companies' efforts to transition patients from drugs nearing the end of their patent life to


D.C. Circuit affirms: FTC can change HSR rules targeted at pharmaceutical patents
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • June 11 2015

In a confluence of IP and antitrust law, a three judge panel for the D.C. Circuit recently affirmed a lower court decision upholding the Federal


Second Circuit antitrust decision creates uncer tainty for non-practice of patents
  • Shook Hardy & Bacon LLP
  • USA
  • June 11 2015

The U.S. Court of Appeals for the Second Circuit's recent decision in New York v. Actavis PLC appeared on its face to address a narrow issue of


A rare victory for doctors in peer review litigation in Texas
  • Kane Russell Coleman & Logan PC
  • USA
  • June 9 2015

On May 22, the Texas Supreme Court handled a physician a rare victory against a health care system in a peer review discovery proceeding. In this


Federal Trade Commission reaches record $1.2 billion proposed “pay for delay” settlement with Cephalon and injunctive relief restricting future similar settlements of patent infringement cases
  • Weil Gotshal & Manges LLP
  • USA
  • June 4 2015

Last week, on the eve of trial, the Federal Trade Commission (“FTC”) reached a proposed settlement in its civil antitrust lawsuit against Cephalon


Second Circuit holds a hard switch between drugs is an unlawful product hop under Section 2
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • June 4 2015

On May 22, 2015, in a much-watched case, the Second Circuit upheld a preliminary injunction against Actavis PLC and its wholly owned subsidiary


Court bars newly adopted Texas telemedicine rules from being implemented
  • Kane Russell Coleman & Logan PC
  • USA
  • June 3 2015

On April 10, 2015, the Texas Medical Board agreed to adopt revisions to Texas Administrative Code 190.8(1)(L) that would dramatically restrict


Federal Trade Commission continues march “to set a standard for the industry” with Cephalon settlement
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • June 3 2015

On May 28, the Federal Trade Commission (“FTC”) announced it had reached a $1.2 billion settlement with Teva Pharmaceuticals, which acquired